La cadena de opciones muestra datos clave de las opciones de acciones de Upexi a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Upexi..

Upexi (NASDAQ:UPXI) Bolsa, Cadena de Opciones

Upexi

Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.

Upexi Inc

<ul>
<li>Independent study published in Gland Surgery and conducted at Kameda Medical Center in Japan by ProSense&#xAE; users including Dr. Kizuki Matsumoto and Dr. Eisuke Fukuma</li>
<li>Patients who underwent cryoablation compared to breast-conserving therapy (BCT) reported significantly higher satisfaction (71.0±18.6 vs. 56.3±16.5) in the primary outcome with a mean follow-up of 4.2 and 4.0 years, respectively</li>
<li>Data support continued move toward de-escalation of breast cancer treatment from BCT (lumpectomy) to nonsurgical options including cryoablation</li>
</ul>
CAESAREA, Israel, March 10, 2025 /PRNewswire/ -- <a href="https://icecure-medical.com/">IceCure Medical Ltd.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study titled 'Post-treatment patient satisfaction in early-stage breast cancer: Comparison of cryoablation versus breast conservation therapy using BREAST-Q' in the peer reviewed journal <a href="https://gs.amegroups.org/article/view/134973/html">Gland Surgery</a>. The study was conducted at the Breast Center, Kameda Medical Center in Kamogawa, Chiba, Japan by the co-authors of the article, Dr. Kizuki Matsumoto, Dr. Yuko Asano, Dr. Hiroki Matsui, and Dr. Eisuke Fukuma. A leading expert and breast surgeon, Dr. Eisuke Fukuma has performed over 600 ProSense&#xAE; breast cryoablation procedures, has presented on ProSense&#xAE; and has trained other doctors at medical conferences.
In Japan, the de-escalation of treatment for breast cancer continues, with breast-conserving therapy ("BCT"), typically defined as standard of care breast surgery or lumpectomy, representing approximately 60% of all breast cancer cases, as novel nonsurgical options have emerged.

Biotech

News

General

ICCM

IceCure Medical Announces The Publication Of An Independent Study Titled 'Post-Treatment Patient Satisfaction In Early-Stage Breast Cancer: Comparison Of Cryoablation Versus Breast Conservation Therapy Using BREAST-Q' In The Peer Reviewed Journal Gland Surgery

Evercore ISI Group analyst Amit Daryanani initiates coverage on Karman Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRMN#NYSE">KRMN</a>) with a Outperform rating and announces Price Target of $38.

Price Target

Initiation

Analyst Ratings

KRMN

Evercore ISI Group Initiates Coverage On Karman Holdings with Outperform Rating, Announces Price Target of $38

New Solution Supports Growing Demand for AI-Enabled Research &amp; Development Market,&nbsp;Enabling Research Efficiency To Meet Modern Demands
HENDERSON, Nev., March 10, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4379255-1&amp;h=3036893744&amp;u=https%3A%2F%2Fwww.researchsolutions.com%2F&amp;a=Research+Solutions">Research Solutions</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSSS#NASDAQ">RSSS</a>), a leader in AI-powered scientific research software, announces the launch of an innovative solution that allows customers to purchase legal rights to use scientific journal content within AI applications. For articles from participating publishers, AI use rights can be acquired in the same checkout flow as purchasing articles on the platform and can be purchased retroactively for articles previously purchased.
With this new solution, Research Solutions establishes itself as the definitive bridge between enterprise AI capabilities and scientific content, creating new opportunities for sustainable growth while helping shape the future of research.

RSSS

Research Solutions Announces The Launch Of An Innovative Solution That Allows Customers To Purchase Legal Rights To Use Scientific Journal Content Within Ai Applications.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst John Colantuoni upgraded the rating for Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from Hold to Buy and raised the price target from $165 to $185. Airbnb shares closed at $134.39 on Friday. <a href="https://www.benzinga.com/quote/ABNB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Mark Murphy upgraded DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) from Underweight to Neutral and raised the price target from $70 to $75. DocuSign shares closed at $79.83 on Friday. <a href="https://www.benzinga.com/quote/DOCU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Keith Horowitz upgraded KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) from Neutral to Buy and announced a $20 price target. KeyCorp shares closed at $15.73 on Friday. <a href="https://www.benzinga.com/quote/KEY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Ryan Merkel upgraded the rating for Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) from Market Perform to Outperform. Fastenal shares closed at $79.98 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Ryan Merkel upgraded W.W. Grainger, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) from Market Perform to Outperform. W.W. Grainger shares closed at $1,007.71 on Friday. <a href="https://www.benzinga.com/quote/GWW/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ABNB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10084512/image-49-1024x582.png" alt="" class="wp-image-816573" style="width:545px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10084512/image-49-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10084512/image-49-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10084512/image-49-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10084512/image-49.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

ABNB

DOCU

FAST

This Airbnb Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

SUNation Energy, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>), a leading provider of sustainable solar energy and backup power solutions for households, businesses, and municipalities, today announced that Chief Operating Officer James Brennan has assumed the title and additional responsibilities of Chief Financial Officer, effective March 5, 2025.
Mr. Brennan, who joined SUNation in 2015 and was appointed Chief Operating Officer in 2022, brings more than 30 years of domestic and international experience in M&amp;A, finance, strategy, corporate development, sales and marketing to his new role.

Management

SUNE

SUNation Energy Appoints James Brennan Chief Financial Officer, Effective March 5, 2025

Phase 3 MARIPOSA study showed&nbsp;LAZCLUZE&#xAE; plus RYBREVANT&#xAE; significantly improved progression-free survival, reducing the risk of disease progression or death by 30 per cent versus osimertinib alone.1
TORONTO, March 10, 2025 /CNW/ - Johnson &amp; Johnson (NYSE:&nbsp;JNJ) announced today that Health Canada has issued a Notice of Compliance (NOC) for LAZCLUZE&#xAE; (lazertinib) in combination with RYBREVANT&#xAE; (amivantamab) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.1 Janssen Inc., a Johnson &amp; Johnson company, is the market authorization holder for LAZCLUZE &#xAE; and RYBREVANT&#xAE; in Canada.
With this authorization, LAZCLUZE&#xAE; plus RYBREVANT&#xAE; becomes the first and only chemotherapy-free combination regimen showing clinically meaningful and statistically significant improvement in progression-free survival versus osimertinib for these patients.1 RYBREVANT&#xAE; is a fully human bispecific antibody targeting EGFR and MET with immune cell-directing activity, and LAZCLUZE&#xAE; is a highly potent, brain penetrant,2 third-generation&nbsp;EGFR tyrosine kinase inhibitor (TKI).3,1

Global

Johnson & Johnson Announces Health Canada Authorizes LAZCLUZE In Combination With RYBREVANT As A First-Line Chemotherapy-Free Treatment For Patients With EGFR-Mutated Advanced Lung Cancer

Evercore ISI Group analyst Peter Levine initiates coverage on SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Outperform rating and announces Price Target of $29.

SAIL

Evercore ISI Group Initiates Coverage On SailPoint with Outperform Rating, Announces Price Target of $29

<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40857265/kraken-pushes-back-against-sec-lawsuit-demands-jury-trial">Cryptocurrency exchange Kraken</a> is preparing to go public, capitalizing on improved regulatory conditions in the United States under President Donald Trump's administration.
The company, legally registered as Payward Inc., is reportedly planning an initial public offering as early as the first quarter of next year.
What Happened: While the decision is not yet finalized, sources familiar with the matter indicate that Kraken is actively working towards a public listing, <a href="https://www.bloomberg.com/news/articles/2025-03-07/crypto-exchange-kraken-said-to-prepare-for-ipo-in-2026">according</a> to a Bloomberg report on Mar. 7.
In a statement addressing the speculation, Kraken emphasized its dedication to financial transparency. 
"We recently disclosed our 2024 financial highlights to improve transparency, following our lead in publishing proof-of-reserves. We will continue prioritizing openness and will pursue public markets when it aligns with the interests of our clients, partners, and shareholders," the company said.
Kraken has long considered going public, but its plans were hindered by regulatory enforcement actions during the Biden administration. 
The company <a href="https://www.benzinga.com/government/regulations/25/03/44100314/sec-drops-lawsuit-against-crypto-exchange-kraken-ceo-calls-it-massive-win-bayc-nft-creator-yuga-labs-also-gets-reprieve">settled one case with the U.S. Securities and Exchange Commission</a> and fought another until the agency ultimately dropped it without imposing any penalties.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44206614/jpmorgan-questions-viability-of-us-crypto-reserve-cites-issues-with-smaller-tokens">JPMorgan Questions Viability of US Crypto Reserve, Cites Issues With Smaller Tokens</a>
Why It Matters: Under Trump, the regulatory environment has shifted, creating new opportunities for crypto firms.
The president has openly supported the industry and is set to meet with over two dozen crypto executives, including Kraken Co-CEO Arjun Sethi, at the White House on Friday.
Kraken's financial performance has strengthened amid the broader recovery in cryptocurrency markets. 
The company's revenue more than doubled in 2024, reaching $1.5 billion, with adjusted earnings of $380 million. 
In comparison, Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), the largest U.S.-based crypto exchange, reported around $6.6 billion in revenue for the same period.
Globally, Kraken ranks among the top ten crypto exchanges by trading volume and has been expanding its services in multiple markets. 
The company has also been developing new financial products to meet increasing demand. 
Kraken is one of several crypto firms eyeing a public listing as IPO activity in the sector gains momentum. 
Other firms reportedly considering going public include stablecoin issuer Circle (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>), digital asset custodian BitGo, and exchanges such as Gemini and Bullish.
Since its founding in 2011, Kraken has raised approximately $27 million in primary funding, a relatively small amount compared to its industry peers. 
With its IPO plans progressing, industry observers are closely monitoring how the company navigates its next phase of growth in a changing regulatory landscape.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44205349/michael-saylor-hints-us-will-buy-1-million-bitcoin-for-strategic-reserve">Michael Saylor Hints US Will Buy 1 Million Bitcoin For Strategic Reserve</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$USDC

COIN

Crypto Exchange Kraken Sets Sights On 2025 Initial Public Offering

Topline results also show investigational&nbsp;targeted oral peptide&nbsp;icotrokinra&nbsp;achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study
Clinical response and remission rates continued to improve through Week 28, building on strong data recently reported for the plaque psoriasis Phase 3 program
Icotrokinra demonstrates potential to offer therapeutic benefit and tolerability with a once daily oral treatment
SPRING HOUSE, Pa., March 10, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:&nbsp;JNJ)&nbsp;today announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra (JNJ-2113), the first investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). The study met its primary endpoint of clinical responsea in all icotrokinra dose groups evaluated and demonstrated clinically meaningful differences versus placebo in key secondary endpoints of clinical remissionb, symptomatic remission and endoscopic improvement at Week 12.&nbsp;
In the ANTHEM-UC study (n=252), three doses of once daily icotrokinra were tested with all meeting the primary endpoint of clinical response at Week 12. A response rate of 63.5% for patients treated with the highest dose of icotrokinra was achieved at Week 12 versus 27% for placebo (p&lt;0.001). Further, 30.2% of patients treated with the highest dose of icotrokinra demonstrated clinical remission at Week 12 versus 11.1% of patients who received placebo (p&lt;0.001). Remission and response rates continued to improve through Week 28.1
Icotrokinra was well tolerated with proportions of participants reporting one or more adverse events (AEs) being similar between the icotrokinra dose groups and the placebo group.1

Johnson & Johnson Announces Icotrokinra Meets Primary Endpoint Of Clinical Response In Ulcerative Colitis Study And Shows Potential To Transform The Treatment Paradigm For Patients

Chardan Capital analyst Daniil Gataulin maintains Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) with a Buy and maintains $6 price target.

Chardan Capital Maintains Buy on Unity Biotechnology, Maintains $6 Price Target

Baird Medical Investment Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) ("Baird Medical" or the "Company"), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology,&nbsp;has received regulatory approval from the Indonesian Ministry of Health (Kementerian Kesehatan Republik Indonesia). This approval includes the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle, laying the foundation for Baird Medical to introduce its advanced minimally invasive treatment solutions across Indonesia.

BDMD

Baird Medical Secures Indonesian Regulatory Approval For Microwave Ablation Technology

Recently, the World Bank estimated that there were 1.4 billion unbanked and many more underbanked people globally. The <a href="https://www.weforum.org/stories/2024/07/why-financial-inclusion-is-the-key-to-a-thriving-digital-economy/#:~:text=The%20World%20Bank%20estimates%20that,in%20the%20global%20financial%20landscape.">lack of access to financial services</a> is a significant burden for underserved populations, making it harder to get loans and bridge financial gaps, which hurts personal finances and makes it harder to escape poverty.
Lack of access to capital in markets in areas such as Africa, most of Eastern Europe and some parts of Latin America, the Middle East, Russia and Southeast Asia also makes it harder for businesses in these markets to grow. According to the United Nations, &#8220;micro, small and medium enterprises (MSMEs) account for 90% of businesses, more than 70% of employment and 50% of GDP worldwide.&#8221;
Alex Vert, <a href="https://www.linkedin.com/in/alex-vert-fintech/">founder of LendSwap</a>, says web-based solutions incorporating Artificial Intelligence (AI) can help break the cycle of deprivation, bring more people into the global financial system, and ultimately help individual businesses grow in a way that better positions growth.
&#8220;Traditional banks often find it unprofitable to offer certain services, such as microloans, or they face regulatory restrictions that prevent them from doing so. LendSwap fills this void by providing access to financial services that would otherwise be unavailable,&#8221; Vert said.
Emerging economies like Vietnam, Mexico, Nigeria and India hold significant potential but remain underserved by traditional financial systems. According to the World Bank, over 65% of individuals and small businesses in these regions face financing constraints due to collateral requirements, slow approval processes, high interest rates, and unsustainable repayment terms.
Decentralized digital currencies, most prominently Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), tend to gain popularity during global economic and political uncertainty as institutional and retail consumers look for a safe haven, independent of the state where they can store value. Vert sees the world as ready for decentralized financing, even in emerging markets, as the Web2 world evolves into Web3.
&#8220;We see this shift toward a decentralized, AI-powered financial system as overwhelmingly positive. An open liquidity market will unlock millions of new users for Web3, reduce fees, improve transparency, and make blockchain-based finance an integral part of everyday life through continuous innovation and new financial tools.&#8221;
LendSwap uses AI to streamline the loan application, approval and disbursement processes. AI-driven risk assessment models make quick approvals without the need for human intervention. Approved loans, in turn, trigger the instant release of funds.
&#8220;We firmly believe that the future of financial services will be centered around Web3. While traditional banks and NBFIs already use AI, these institutions remain opaque, charge high fees, and are burdened with bureaucratic inefficiencies and liquidity costs. Web3 eliminates many of these issues, making it the logical evolution of the industry,&#8221; Vert says.
LendSwap says it serves over 11 million customers with a projected goal of reaching 100 million users in the next two years, with the majority of growth in India and Nigeria.
While large tech markets like the U.S. can focus on more specialized use cases like GameFi and memecoins, which address a need for speculation and entertainment, emerging markets have the most substantial need for blockchain services to fill the gaps in traditional financial services.
Liquidity and payments may not be the most disruptive use cases in concept. Still, they are the global use cases most likely to improve users&#8217; lives. A borderless, inclusive financial ecosystem is better for everyone and will ultimately help drive economic progress in markets everywhere.

Emerging Markets

Economics

Exclusives

Interview

$BTC

LendSwap Founder Says AI Tech Can Fill Lending Gaps In Emerging Markets

$911,519 grant awarded for cutting-edge equipment for the recycling of rare earth magnets and battery materials
Indiana's Recycling Market Development Program awards grants to innovative projects in the recycling sector
Electrified Materials Corporation will expand its preprocessing of end-of-life rare earth magnets, lithium-ion batteries and ferrous metals, ensuring a sustainable domestic supply chain for copper, aluminum, steel, plastic and critical minerals
FISHERS, IN / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / March 10, 2025 / American Resources Corporation's <a href="https://pr.report/8464">(NASDAQ:</a><a href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) ("American Resources") announced that its wholly-owned subsidiary, Electrified Materials Corp ("Electrified Materials" or "EMCO"), has been awarded a $911,519 matching grant under the Indiana Department of Environmental Management's Waste Diversion Project. This initiative aims benefit Indiana's economy by expanding recycling infrastructure for recycling, creating jobs, and addressing supply chain challenges.
Electrified Materials is a cutting-edge recycler of metals to the electrified economy specializing in processing used metals and minerals to be recycled and further refined into new steel-based, battery-grade and magnet-grade products. Today, EMCO operates within the U.S. with its origins in reclaiming former thermal coal mines and industrial sites. By leveraging its regional logistics and infrastructure, along with its affiliation with ReElement Technologies Corporation ("ReElement"), a leader in critical minerals refining, EMCO aims to expand its footprint in the high-growth markets of used steel, rare-earth elements and critical battery materials. Additionally, EMCO remains committed to cleaning up old infrastructure left behind from the declining mining industry. Through its affiliation and collaboration with ReElement, EMCO will preprocess end-of-life waste containing critical minerals, such as wind turbines, EV motors, lithium-ion batteries, consumer power tools and e-waste, before supplying these concentrates to ReElement for further refinement into manufacturing-grade final products, ready to reenter the supply chain.

Contracts

AREC

American Resources Corp's Electrified Materials Has Been Awarded A $911,519 Matching Grant Under The Indiana Department Of Environmental Management's Waste Diversion Project

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) is &#8220;one of the <a href="https://www.benzinga.com/quote/FI">greatest fintechs.&#8221;</a>
As per recent news, Fiserv announced on March 3 that it had completed its acquisition of Payfare Inc.
When asked about Farmland Partners Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FPI#NYSE">FPI</a>), he said, &#8220;I kind of like the idea as a spec.&#8221;
On the earnings front, Farmland Partners, on Feb. 19, reported better-than-expected fourth-quarter financial results and issued FY25 FFO guidance above estimates.
Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) reported a &#8220;bad&#8221; quarter, Cramer said, &#8220;There are several things that are definite misses. It does deserve to trade lower.&#8221;
On Feb. 25, Sempra posted fourth-quarter adjusted earnings of $1.50 per share, missing market estimates of $1.60 per share. The company's sales came in at $3.76 billion, falling short of expectations of $4.36 billion.
When asked about Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), he said, &#8220;We're going to have to hold off.&#8221;
On Feb. 28, Recursion Pharmaceuticals posted worse-than-expected fourth-quarter financial results.
Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) is a &#8220;meme&#8221; stock,&#8221; the Mad Money host said. &#8220;It is not trading on the fundamentals.&#8221;
As per the recent earnings report, Rigetti Computing, on March 5, reported fourth-quarter revenue of $2.3 million, missing a Street consensus estimate of $2.5 million according to data from Benzinga Pro.
Cramer recommended to own ONEOK, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>). &#8220;I think ONEOK may be the best-run pipeline company in the country,&#8221; he added.
Supporting his view, ONEOK, on Feb. 24, posted better-than-expected quarterly earnings.
&#8220;There are still remedies that are needed. Until all the remedies happen, I am not going to approve it,&#8221; Cramer said when asked about Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).
On March 3, JPMorgan maintained an Underweight rating on the stock, saying its filling revealed material weaknesses.
Price Action:
<ul>
<li>Fiserv shares fell 0.9% to settle at $218.04 on Friday.</li>
<li>Sempra shares slipped 0.5% to close at $69.30 during the session.</li>
<li>Rigetti Computing shares jumped 9.9% to settle at $9.35.</li>
<li>Recursion Pharmaceuticals shares climbed 5.6% to close at $6.59 on Friday.</li>
<li>ONEOK shares fell 0.2% to settle at $89.57.</li>
<li>Farmland Partners shares gained 0.5% to close at $11.15.</li>
<li>Super Micro Computer shares gained 3.2% to close at $38.24 on Friday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>
Image: Shutterstock

Media

First Trust Advantage Preferred Income Fund

RGTI

RXRX

SMCI

Jim Cramer: Fiserv Is 'One Of The Greatest Fintechs,' Calls This Tech Company A Meme Stock

B of A Securities analyst Jason Kupferberg maintains Paysafe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) with a Underperform and lowers the price target from $18 to $16.

PSFE

B of A Securities Maintains Underperform on Paysafe, Lowers Price Target to $16

On March 7, 2025, Volcon ePowersports ("Volcon" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>), a provider of electric vehicles today announced that its Board of Directors has authorized a share repurchase program, allowing for the repurchase of up to $2 million of the Company's common stock through March 7, 2026.

Buybacks

VLCN

Volcon Announces Board Authorization Of $2M Share Repurchase Program

B of A Securities analyst Joshua Shanker maintains Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) with a Buy and lowers the price target from $333 to $318.

B of A Securities Maintains Buy on Progressive, Lowers Price Target to $318

BloomZ Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) ("BloomZ" or the "Company"), a Japanese audio production, VTuber, entertainment, and voice actor management company, announced the appointment of Ryoshin Nakade as the co-Chief Executive Officer and co-Chairman of the Board, effective March 7, 2025. In this role, Mr. Nakade will serve alongside co-Chief Executive Officer Kazusa Aranami to lead the Company into its next phase of growth.

BLMZ

BloomZ Appoints Ryoshin Nakade As Co-Chief Executive Officer And Co-Chairman Of The Board

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
Clears the way to finalize Phase 3 protocol and recruit sites for U.S.
Phase 3 substantially funded by $17.0 million CPRIT grant and $8.5 million Company match
Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the results of its Type C meeting with the U.S. Food and Drug Administration ("FDA") regarding the protocol for the planned registrational Phase 3 study of eRapa in familial adenomatous polyposis ("FAP").
The Type C meeting followed a productive End of Phase 2 meeting with FDA and the publication of Phase 2 data of eRapa in FAP at six months at Digestive Disease Week in May 2024 and 12 months data at InSight, Barcelona in June 2024. The Type C meeting included a discussion of the statistical plan, the safety database and, most importantly, a composite endpoint for the Phase 3 study. FDA representatives from both Gastroenterology and Oncology Divisions provided valuable input into the proposed program and the Company believes there is a clear path forward for initiation of the registrational Phase 3 study in FAP in the U.S. next quarter.
The planned registrational Phase 3 study of eRapa in FAP will be a double-blind placebo-controlled trial in 168 patients, randomized 2:1 drug / placebo. It is expected the study will be conducted in approximately 30 clinical sites across the US and Europe. The US component of the study will be conducted by LumaBridge, based in San Antonio, Texas and the European component will be conducted by Precision for Medicine LLC. The Phase 3 study is supported by a $17.0 million grant from the Cancer Prevention Research Institute of Texas ("CPRIT") and a Company match of $8.5 million which has already been paid, in full, into escrow.

BDRX

Biodexa Announces Outcome Of Type C Meeting With FDA Regarding The Phase 3 Program For eRapa In FAP; Clears The Way To Finalize Phase 3 Protocol And Recruit Sites For U.S.

B of A Securities analyst Tal Liani initiates coverage on SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Buy rating and announces Price Target of $27.5.

Comments

Upexi

Upexi (UPXI) Opciones

Upexi (NASDAQ:UPXI) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL